Akcea Therapeutics Inc. announced that the U.S. Food and Drug Administration’s Division of Metabolism and Endocrinology Products Advisory Committee voted 12-8 to support approval of Waylivra (volanesorsen) for the treatment of people with familial chylomicronemia syndrome.
Shares of Pacira Pharmaceuticals plunged more than 15 percent after the company revealed a U.S. Food and Drug Administration advisory panel recommended against approving expanded use of the company’s pain treatment Exparel.
Seasonal flu has been widespread in 2018, impacting millions of people across the country. It has been an especially challenging season, with high rates of hospitalization for both influenza and its complications, which include pneumonia and the exacerbation of chronic conditions such as asthma and congestive heart failure. Many schools have closed in an attempt to control the spread of the illness and doctor’s offices are packed with patients seeking diagnosis and antiviral treatment.
Here are five companies looking at possible drug approvals in January 2018.